In-house Healthcare global Company newsroom

Sanofi

Real-time Analytics · Supply Chain Optimization

Sanofi needs to accelerate biopharma development, manufacturing, and supply so it can bring medicines to patients faster, increase production efficiency, and make operations more predictive and resilient across its global Manufacturing & Supply network.

already identified seven new therapeutic targets
shorten the time it takes to bring new medicines to market by up to one year
triple the number of new medicines we launch

Reported impact

Business outcome

Sanofi reports that its AI program is helping shorten time-to-market, improve efficiency, make production more agile and predictive, strengthen supply chain resilience, identify new therapeutic targets, and improve predictive accuracy for personalized medicine.

  • Productivity Improvement
  • Scalability
  • Speed to Market

Solution

Sanofi describes an in-house AI transformation program centered on its Digital Accelerator network, with the newest accelerator focused on Manufacturing & Supply. In this implementation, Sanofi uses Digital twins to run virtual production simulations before or alongside physical operations, helping teams test scenarios and improve production decisions. It also combines AI + Internet of Things (IoT) for real-time monitoring and predictive decision-making across the manufacturing value chain, indicating that operational signals from industrial processes are captured continuously and used by AI-driven models. The company says it is also using scalable platforms to strengthen global supply chain resilience, while related Patient Digital Twin technology improves predictive accuracy for personalized medicine. The page does not name a separate storage platform, external cloud, or serving layer, but it clearly places AI inside production, R&D, and supply workflows rather than treating it as a future aspiration.

Data flow

Operational manufacturing signals and IoT monitoring data are captured from Sanofi's manufacturing value chain, analyzed with AI-driven models, and used inside digital twin simulations and predictive decision workflows. The resulting insights feed manufacturing, supply, and R&D teams so production, resilience, and medicine delivery decisions can be made faster.

Solution architecture

3 components · 2 layers
  1. Compute
    • Digital twins Run virtual production simulations to support manufacturing decisions.
    • Patient Digital Twin technology Improve predictive accuracy to support more personalized medicine.
  2. Uncategorized
    • AI + Internet of Things (IoT) Use real-time monitoring data and AI for predictive decision-making in manufacturing operations.

Architecture clues

  • AI is applied across the development lifecycle from early research to commercial manufacturing.
  • Cross-functional team includes data science, software engineering, and user experience experts.
  • Newest Digital M&S Accelerator is located in Lyon, France.
  • Scalable platforms are used to enhance global supply chain resilience.
  • Third Digital Accelerator is dedicated to the digital transformation of Sanofi's global Manufacturing & Supply network.

Evidence from the source

"At our newest Digital M&S Accelerator in Lyon (France) ... deploying Digital twins for virtual production simulations, AI + Internet of Things (IoT) for real-time monitoring and predictive decision-making"
"Our second accelerator, launched in early 2024 and focused on R&D has already identified seven new therapeutic targets."
"We’re aiming to triple the number of new medicines we launch"
"We’re applying AI across the entire development lifecycle — from early research to commercial manufacturing — to shorten the time it takes to bring new medicines to market by up to one year."
"accelerate the path from scientific discovery to patient delivery by embedding Artificial Intelligence into every facet of pharmaceutical production — reducing time-to-market, increasing efficiency"
"scalable platforms to enhance global supply chain resilience"
Transparency Evidence & methodology 70/100 reference value · 92% confidence · 1 source

Review how this reference was scored and trace each normalized claim back to its documented source.

01

Scoring methodology

How scores are calculated

Customer Reference Value measures usefulness as a customer reference. Evidence Confidence measures the quality and traceability of available evidence, not independent verification.

Customer reference value70/100
  • Problem clarity20/20
    Measures whether the customer's operational problem is specific enough to compare.
  • Implementation depth20/25
    Rewards named components, data flow, integrations, and architecture detail.
  • Outcome specificity20/20
    Measures whether the reported benefit is concrete rather than a generic claim.
  • Quantified impact0/25
    0 metrics describe measurable impact.
  • Deployment scale10/10
    Rewards evidence of a live or scaled deployment and meaningful integration scope.
Evidence confidence92%
  • Source authority25/25
    The deployment is described by the adopting organization or a government source.
  • Claim traceability21/25
    10 of 12 key fields link to a named source.
  • Direct evidence20/20
    6 direct source quotes retained.
  • Date provenance10/10
    The publication date comes from the source page or publisher.
  • Source transparency8/10
    1 source reference document publisher, URL, authority, retrieval, and supported fields.
  • Implementation specificity8/10
    Rewards source-backed components, data flow, quantified impact, and a specific outcome.
02

Traceability

Sources & provenance

Field coverage shows which facts each source supports. Dates are shown only when documented by the source.

  1. Sanofi

    Sanofi customer story

    First-party
    https://www.sanofi.com/en/magazine/ai-in-healthcare/a-new-era-of-biopharma-production-with-ai
    Source type
    Customer-published story
    Published
    May 28, 2025
    Supports
    • Customer
    • Business problem
    • Solution
    • Products
    • Solution components
    • Data flow
    • Integrations
    • technical area
    • use case category
    • Business outcome
    • outcome category
    • Metrics
    • Architecture
    • evidence quotes
    • Publication date

Date evidence

  • Published on source page May 28, 2025 · Sanofi · First-party
    Open date source
Not separately sourced Industry, Region, Company size. Treat these normalized attributes as lower-confidence until a dedicated source is added.